Jim Cramer on what is driving Eli Lilly's stock right now

Group 1 - Eli Lilly's stock performance is influenced more by new reports on GOP-1 clinical trials than by its earnings [1] - Alphabet is highlighted as a strong performer, with significant contributions from its products like Gemini, YouTube, and self-driving cars [2] - The healthcare sector is facing scrutiny from the president, particularly targeting companies in the healthcare chain [3] Group 2 - The drug distribution sector is criticized for high profits with minimal contributions to healthcare, with McKesson being implied as a key player [4] - Amazon's stock has become volatile, with earnings reports leading to significant fluctuations in its stock price [5] - The travel sector is mentioned as a focus for investment, despite recent underperformance [6]